Sun Gets GMP Warning Letter Over Imploding Samples, Languid Recall
Executive Summary
Inadequate written procedures for production and process controls and failure to investigate out-of-specification results prompted an FDA warning letter Aug. 25 to Sun Pharmaceutical Industries, headquartered in Mumbai, India